Pfizer (NYSE:PFE) Receives Neutral Rating from Cantor Fitzgerald

Posted by Logan Wallace on Jul 7th, 2026

Cantor Fitzgerald reissued their neutral rating on shares of Pfizer (NYSE:PFE – Free Report) in a research report released on Monday morning,Benzinga reports. Cantor Fitzgerald currently has a $27.00 target price on the biopharmaceutical company’s stock.

A number of other research firms have also recently commented on PFE. CICC Research began coverage on Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 target price on the stock. Bank of America reduced their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Citigroup raised their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 29th. Guggenheim upped their target price on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Finally, HSBC downgraded shares of Pfizer from a “buy” rating to a “hold” rating and decreased their price target for the company from $32.00 to $28.00 in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.59.

Read Our Latest Stock Analysis on Pfizer

Pfizer Price Performance

Shares of PFE stock traded up $0.44 on Monday, reaching $24.16. The company’s stock had a trading volume of 5,142,613 shares, compared to its average volume of 42,545,309. The company has a market capitalization of $137.68 billion, a price-to-earnings ratio of 18.44 and a beta of 0.35. The stock’s fifty day simple moving average is $25.63 and its 200-day simple moving average is $26.23. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer has a 1 year low of $23.11 and a 1 year high of $28.75.

Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts forecast that Pfizer will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is currently 131.30%.

Hedge Funds Weigh In On Pfizer

Institutional investors have recently modified their holdings of the business. CoreCap Advisors LLC increased its stake in shares of Pfizer by 5.6% during the second quarter. CoreCap Advisors LLC now owns 85,905 shares of the biopharmaceutical company’s stock worth $2,069,000 after buying an additional 4,584 shares during the period. Howard Financial Services LTD. increased its holdings in shares of Pfizer by 13.9% in the 2nd quarter. Howard Financial Services LTD. now owns 12,628 shares of the biopharmaceutical company’s stock valued at $304,000 after acquiring an additional 1,539 shares during the last quarter. Boltwood Capital Management boosted its holdings in Pfizer by 2.6% in the second quarter. Boltwood Capital Management now owns 58,299 shares of the biopharmaceutical company’s stock valued at $1,404,000 after purchasing an additional 1,480 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Pfizer by 1.6% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 115,825 shares of the biopharmaceutical company’s stock valued at $2,789,000 after buying an additional 1,773 shares in the last quarter. Finally, Hilltop National Bank boosted its stake in Pfizer by 17.8% in the second quarter. Hilltop National Bank now owns 22,328 shares of the biopharmaceutical company’s stock valued at $538,000 after acquiring an additional 3,376 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer is being highlighted as a low-valuation healthcare name, with one article calling it a “dirt cheap” stock to buy in July as investors look for cash-generative Big Pharma franchises trading at bargain multiples. 2 Dirt Cheap Healthcare Stocks to Buy in July
Positive Sentiment: Pfizer received new FDA approval for IBRANCE in HER2-positive breast cancer, adding a fresh catalyst and potentially extending the drug’s commercial relevance. Pfizer (PFE) Wins FDA Approval For IBRANCE In HER2 Positive Breast Cancer
Positive Sentiment: Cantor Fitzgerald reaffirmed Pfizer at Neutral and maintained a $27 price target, implying room above the recent trading level. Pfizer rating reaffirmed by Cantor Fitzgerald
Neutral Sentiment: Pfizer Limited separately announced a July 28 virtual AGM and proposed a final dividend, but this appears to refer to the India-listed Pfizer Limited rather than Pfizer Inc. Pfizer Limited Sets July 28 Virtual AGM, Proposes Rs 75 Final Dividend
Negative Sentiment: Analysts and media reports said Pfizer’s growth story is being delayed by pipeline timing issues, leadership uncertainty, and reduced near-term re-rating potential, contributing to a weaker stock tone. Pfizer’s Growth Story Faces a Wait as Pipeline and Leadership Doubts Mount
Negative Sentiment: Pfizer stock also declined in the latest session as investors rotated into a stronger market, reflecting ongoing skepticism about near-term momentum. Pfizer (PFE) Stock Sinks As Market Gains: Here’s Why

About Pfizer

(Get Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.